Pictet Asset Management
MRNA icon

Pictet Asset Management’s Moderna MRNA Stock Holding History

Pictet Asset Management’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$42M Sell
602,512
-73,605
-11% -$3.81M 0.04% 373
2026
Q1 		$32.8M Sell
676,117
-61,977
-8% -$2.89M 0.03% 389
2025
Q4 		$22.9M Buy
738,094
+3,605
+0.5% +$97.9K 0.02% 499
2025
Q3 		$18.6M Buy
734,489
+51,990
+8% +$1.45M 0.02% 534
2025
Q2 		$18.6M Buy
682,499
+2,751
+0.4% +$72.4K 0.02% 526
2025
Q1 		$20.8M Sell
679,748
-1,086,650
-62% -$38.6M 0.02% 485
2024
Q4 		$73.4M Buy
1,766,398
+1,113,455
+171% +$53.2M 0.08% 245
2024
Q3 		$43.1M Sell
652,943
-461,219
-41% -$42.3M 0.05% 321
2024
Q2 		$132M Sell
1,114,162
-1,507,475
-58% -$191M 0.15% 162
2024
Q1 		$282M Buy
2,621,637
+824,187
+46% +$83.1M 0.31% 84
2023
Q4 		$179M Buy
1,797,450
+407,441
+29% +$34.3M 0.2% 132
2023
Q3 		$144M Buy
+1,390,009
New +$155M 0.18% 152

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Pictet Asset Management's MRNA Position: Q2 2026 in Review

Pictet Asset Management reduced its Moderna (MRNA) stake by 11% in Q2 2026, selling an estimated $3.81M and leaving 602,512 shares worth $42M. The position accounts for 0.04% of the portfolio, ranked #373.

Pictet Asset Management first reported a position in MRNA in Q3 2023 and has held it in 12 quarters since. The position peaked at $282M in Q1 2024. 782 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Pictet Asset Management held 602,512 shares of Moderna worth $42M as of Q2 2026.
  • Pictet Asset Management sold 73,605 Moderna shares in Q2 2026, an estimated $3.81M.
  • Moderna made up 0.04% of Pictet Asset Management's portfolio in Q2 2026, its #373 holding.
  • Pictet Asset Management first reported a position in Moderna in Q3 2023 and has held it in 12 quarters since.
  • Pictet Asset Management's Moderna position peaked at $282M in Q1 2024.
  • 782 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Pictet Asset Management's 13F filing for Q2 2026, filed 30 Jul 2026.